Stock Selection: Grok 4.7's picks for 2026-11-03
Grok 4.7 picked IDXX, LSCC, NBIX, FN, RVTY for a 1-day horizon. Portfolio return vs SPY: -4.97%. Picks that beat SPY: 20%.
| Experiment | Stock Selection |
|---|---|
| Model | Grok 4.7 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-11-03 |
| Measured to | 2026-11-04 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | -4.97% |
| Picks that beat SPY | 20% |
| Benchmark return | +1.19% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | IDXX | +3.56% | 75% | +2.37% | Yes |
| 2 | LSCC | -6.68% | 72% | -7.87% | No |
| 3 | NBIX | -1.51% | 70% | -2.70% | No |
| 4 | FN | -7.68% | 68% | -8.87% | No |
| 5 | RVTY | -6.60% | 65% | -7.79% | No |
The model's market view
Mixed session with selective strength in earnings-driven names. Quality catalysts in diagnostics, semiconductors, and life sciences are supporting continued upside relative to a still-selective broader tape.
Why each pick
IDXX
IDXX is holding near yesterday’s close after a 21.85% surge on a clear Q3 earnings beat ($4.01 vs $3.71 est) with raised full-year guidance and record instrument placements. Relative volume was elevated and the stock closed near the high of the day. Residual absorption of the fundamental surprise should support further gains versus SPY. Risks: profit-taking after the large prior-day move or broader healthcare multiple compression.
LSCC
Lattice Semiconductor is up roughly 14-15% today on strong visibility and outlook commentary pointing to robust growth into 2028. Volume is well above average. The semiconductor demand signal is not fully priced relative to the elevated run-rate commentary; continuation expected. Risks: broader semiconductor volatility or profit-taking after the sharp intraday move.
NBIX
Neurocrine is up 13-15% today after reporting a strong Q3 beat (non-GAAP EPS $3.29 vs $2.75 consensus, product sales exceeding $1B for the first time) with positive commentary on volume growth. Volume is elevated. The earnings surprise and guidance tone should continue to support outperformance versus SPY. Risks: any fade of the post-earnings pop or broader biotech weakness.
FN
Fabrinet is up approximately 16% today after reporting record fiscal Q1 revenue (+51% YoY) that beat guidance and issuing strong Q2 revenue guidance of $1.6-1.65B. Volume is elevated relative to average. The optical packaging demand strength is not fully digested; further upside likely. Risks: capacity ramp execution risk or broader tech rotation.
RVTY
Revvity is up 11-12% today after a Q3 earnings and revenue beat (adjusted EPS $1.37 vs $1.30 est, revenue $729M) and raised full-year guidance. Volume is elevated. The life-sciences tools momentum and guidance raise support continued outperformance versus SPY. Risks: valuation after the strong year-to-date move or any softening in end-market commentary.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| Claude Opus 5.5 | FISV, IDXX, HWM, RVTY, FN | -3.75% | 40% |
| Claude Sonnet 5.5 | OKTA, IDXX, FN, TEM, AMD | -3.70% | 20% |
| GPT-6 | FN, HWM, NXT, AMD, IDXX | -1.50% | 40% |
| GPT-6.1 Sol | IDXX, REGN, FN, HWM, NXT | -1.52% | 40% |
| Muse Spark 1.1 | AMD, IDXX, SHOP, SUPN, LITE | -3.31% | 40% |
| Perplexity | IDXX, HWM, RIVN, PNR, SHW | +0.66% | 80% |
| Gemini 3 Pro | AEHR, FN, NBIX, RVTY, LSCC | -7.06% | 0% |
| DeepSeek | UPWK, TEVA, AEHR, HLIT, ON | -4.82% | 0% |
Written up on ForecastNest Insights: Stock Selection: Grok 4.7's picks for 2026-11-03.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.